DDInter1666 DDInter1951
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Sildenafil {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Warfarin
Sildenafil {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Sildenafil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Warfarin
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Warfarin
Sildenafil {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Sildenafil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Procarbazine
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Sildenafil {u} (Compound) binds {v} (Gene) PDE6C
PDE6C {u} (Gene) is bound by {v} (Compound) Dipyridamole
Dipyridamole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Sildenafil {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Tamoxifen
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Sildenafil (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Warfarin (Compound)
Sildenafil (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin
Sildenafil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Warfarin (Compound)
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Warfarin (Compound)
Sildenafil (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Fluvastatin (Compound) and Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin
Sildenafil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin
Sildenafil (Compound) binds PDE6C (Gene) and PDE6C (Gene) is bound by Dipyridamole (Compound) and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Sildenafil (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Warfarin
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin